United Biomedical Incorporated-Asia
United Biomedical Incorporated-Asia (UBI-Asia), headquartered in Taiwan (TW), is a prominent player in the biotechnology and pharmaceutical industry. Founded in the early 2000s, UBI-Asia has established itself as a leader in the development of innovative diagnostic solutions and therapeutic products, particularly in the fields of immunology and infectious diseases. With a strong operational presence across Asia, UBI-Asia focuses on delivering unique, high-quality products that cater to the evolving needs of healthcare professionals and patients. Their core offerings include advanced diagnostic kits and therapeutic agents, distinguished by their precision and reliability. Recognised for its commitment to research and development, UBI-Asia has achieved significant milestones, positioning itself as a trusted name in the market. The company continues to drive advancements in biotechnology, contributing to improved health outcomes across the region.
DitchCarbon Score
How does United Biomedical Incorporated-Asia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
United Biomedical Incorporated-Asia's score of 0 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
United Biomedical Incorporated-Asia's reported carbon emissions
United Biomedical Incorporated-Asia, headquartered in Taiwan (TW), currently does not have available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is challenging to assess their climate impact or sustainability efforts. The absence of documented reduction targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises carbon neutrality and sustainability, it will be essential for United Biomedical Incorporated-Asia to establish clear climate commitments and measurable goals to align with global standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
United Biomedical Incorporated-Asia is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
